Nav: Home

Gene sequences reveal global variations in malaria parasites

June 27, 2016

Plasmodium vivax (P. vivax) parasites, which cause a debilitating form of malaria, are yielding their secrets to an international team of researchers funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. In the largest such effort to date, the team determined complete genomes of nearly 200 P. vivax strains that recently infected people in eight countries. Comparative analysis showed the parasites clustered into four genetically distinct populations that provide insights into the movement of P. vivax over time and suggest how it is still adapting to regional variations in both the mosquitoes that transmit it and the humans it infects.

"P. vivax malaria has historically been overshadowed by the more lethal disease caused by P. falciparum parasites," said NIAID Director Anthony S. Fauci, M.D. "However, there are some 16 million cases of clinical malaria due to P. vivax infection worldwide each year, imposing a large public health burden on many countries. The wealth of genomic information provided by this new research shows the high degree of genetic variability in the P. vivax population and gives us a clearer picture of the challenges we face in developing drugs or vaccines against it."

The study, published in Nature Genetics, was led by Jane Carlton, Ph.D., of New York University, and Daniel Neafsey, Ph.D., of the Broad Institute in Cambridge, Massachusetts.

P. vivax parasites have several characteristics that make controlling or eliminating them difficult, Dr. Carlton notes. For example, a dormant form of the parasite can hide in the liver for months at a time, emerging sporadically to cause a fresh bout of fever and weakness in the infected person. P. vivax, she added, cannot be grown in the lab, making it harder to study than other malaria-causing parasite species. Furthermore, the rich genetic diversity of P. vivax strains in most geographic regions sampled means that no single drug or vaccine could be effective against the majority of strains in any one area, much less against all P. vivax strains worldwide. For these reasons, "the research community has always known that P. vivax would be the last malaria parasite standing," said Dr. Carlton.

Dr. Carlton led a team that determined the first genetic sequence of a strain of P. vivax in 2008. In 2012, Drs. Carlton and Neafsey and their colleagues added four additional genomes and determined that P. vivax parasites have twice the genetic diversity of P. falciparum parasites from matched geographic regions. Those studies used P. vivax strains that were originally taken from malaria patients decades earlier and had been modified to grow in monkeys.

In contrast, the new study sequenced P. vivax strains from volunteer blood samples taken recently in eight countries, including Papua New Guinea, India, Thailand, Mexico and several in South and Central America. When added to the countries of origin of the monkey-adapted parasite strains, eleven different countries were represented in the new analysis. Investigators at the Broad Institute developed a technique to increase the amount of parasite DNA in red blood cells and separate it from the much more abundant human DNA also present. The technique allowed them to sequence parasite DNA and, ultimately, to determine near-complete genetic sequences for 182 parasite isolates, said Dr. Carlton. "We confirmed and expanded our earlier findings regarding the extreme genetic diversity in P. vivax compared with P. falciparum" she said.

The four distinct parasite populations the researchers identified clustered into two groups: parasites from New World countries (Brazil, Peru, Colombia and others) differed greatly from those of the Old World countries (Thailand, Myanmar, India and others). P. vivax isolates from Papua New Guinea were genetically distinct from elsewhere in Asia, while strains from Mexico formed a fourth genetic grouping. The strains from Mexico were the least genetically diverse, Dr. Carlton said, which may be because P. vivax cases have declined sharply in that country.

The genomes offer clues to the ways P. vivax has traveled the globe and adapted to mosquito species found in the new regions the parasite was carried to by European traders and colonialists. For example, the P. vivax populations in Central and South America are genetically diverse and distinct from all other sampled regions. This suggests that today's New World parasites may have originated from multiple European sites during the Colonial era and may be descended from now-extinct European parasite lineages.

Dr. Carlton noted the key role played by the NIAID-supported International Centers of Excellence for Malaria Research (ICEMRs) in the new genome study. Investigators from the ICEMR based in Papua New Guinea, for example, had the difficult job of keeping blood samples on dry ice in extremely remote locations, she said. "The study would not have been possible without the ongoing dedication of this large group of collaborators at the participating ICEMRs," Dr. Carlton said.
NIAID grant support for this research included grants U19AI089676, U19AI089681, K24AI068903, U19AI089672, 5U19AI089702, U19AI089686, and T32AI007180. Sequencing and analysis work at the Broad Institute was supported by NIAID contract HHSN272200900018C.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health®

References: DN Hupalo et al. Population genomics studies identify signatures of global dispersal and drug resistance in Plasmondium vivax. Nature Genetics DOI: 10.1038/ng.3588 (2016).

DE Neafsey et alThe malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nature Genetics DOI: 10.1038/ng.2373 (2012).

JM Carlton et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature DOI: 10.1038/nature 07327 (2008).

NIH/National Institute of Allergy and Infectious Diseases

Related Malaria Articles:

Could there be a 'social vaccine' for malaria?
Malaria is a global killer and a world health concern.
Transgenic plants against malaria
Scientists have discovered a gene that allows to double the production of artemisinin in the Artemisia annua plant.
Fighting malaria through metabolism
EPFL scientists have fully modeled the metabolism of the deadliest malaria parasite.
Should we commit to eradicate malaria worldwide?
Should we commit to eradicate malaria worldwide, asks a debate article published by The BMJ today?
Investigational malaria vaccine shows considerable protection in adults in malaria season
An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria -- the deadliest form of the disease -- for the duration of the malaria season, according to new findings published in the Feb.
Why malaria mosquitoes like people with malaria
Malaria mosquitoes prefer to feed -- and feed more -- on blood from people infected with malaria.
Malaria superbugs threaten global malaria control
A lineage of multidrug resistant P. falciparum malaria superbugs has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs), according to a study published today in The Lancet Infectious Diseases.
Considering cattle could help eliminate malaria in India
The goal of eliminating malaria in countries like India could be more achievable if mosquito-control efforts take into account the relationship between mosquitoes and cattle, according to an international team of researchers.
Seasonal malaria chemoprevention in Senegalese children lowers overall malaria burden
Giving preventive antimalarial drugs to children up to age 10 during active malaria season reduced the cases of malaria in that age group and lowered the malaria incidence in adults, according to a randomized trial carried out in Senegal and published in PLOS Medicine by researchers from the Université Cheikh Anta Diop, Senegal, the London School of Hygiene & Tropical Medicine, UK, and other collaborators.
How malaria fools our immune system
OIST researchers reconstruct the 3-D structure of a malaria protein in combination with human antibodies.

Related Malaria Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...